



Multi-center National Registry in the Middle East to Study the Prevalence, Management, Genetic Characteristics and Outcomes of Patients with Familial Hypercholesterolemia in 6 Arabian Gulf Countries

Photos

Steering Committee Meeting, May, 2016, Muscat, Oman.



Lipid Guidelines in the UAE



Lipid Guidelines for the GCC

Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East.

Al Sayed N, Al Waili K, Alawadi F, Al-Ghamdi S, Al Mahmeed W, Al-Nouri F, Al Rukhaimi M, Al-Rasadi K, Awan Z, Farghaly M, Hassanein M, Sabbour H, Zubaid M, Barter P.

Int J Cardiol. 2016 Dec 15;225:268-283. doi: 10.1016/j.ijcard.2016.09.081. Epub 2016 Sep 28. Review.

Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from the Middle East Advisory Panel.

Al-Ashwal A, Alnouri F, Sabbour H, Al-Mahfouz A, Al-Sayed N, Razzaghy-Azar M, Al-Allaf F, Al-Waili K, Banerjee Y, Genest J, Santos RD, Al-Rasadi K.

Curr Vasc Pharmacol. 2015;13(6):759-70.

Familial hypercholesterolemia mutations in the Middle Eastern and North African region: a need for a national registry.

Bamimore MA, Zaid A, Banerjee Y, Al-Sarraf A, Abifadel M, Seidah NG, Al-Waili K, Al-Rasadi K, Awan Z.

J Clin Lipidol. 2015 Mar-Apr;9(2):187-94. doi: 10.1016/j.jacl.2014.11.008. Epub 2014 Nov 29. Review.

IAS OSLA Lipid COURSE 2017



**The Third IAS-OSLA Course on "Lipid Metabolism and Cardiovascular Risk"
Muscat, Oman, February 24-27, 2017
Crown Plaza Hotel**

DAY 1 <i>Friday, February 24</i>	Time (Day 2)	DAY 2 <i>Saturday, February 25</i>	Time (Day 3-4)	DAY 3 <i>Sunday, February 26</i>	DAY 4 <i>Monday, February 27</i>
	7.30 – 8.30	BREAKFAST	7.30 – 8.30	BREAKFAST	BREAKFAST
	8.30 – 9.30	Introductions Pre-Course Test	8.30 – 9.15	LDL, HDL and CVD: Epidemiology and Clinical Trials Philip Barter (Australia)	Genetic Approaches to CVD Prevention and Dyslipidemia Treatment Gilles Lambert (France)
	9.30 – 10.15	Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter (Australia)	9.15 – 10.00	Agents to Reduce LDL (and Future Developments) Raul Santos (Brazil)	Update on Lipid Guidelines Khalid Al-Waili (Oman)
	10.15 – 11.00	Metabolism and Atherogenic Properties of LDL Raul Santos (Brazil)	10.00 – 10.45	Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins, Dimitri Mikhailidis (UK)	Diabetes, Metabolic Syndrome and CVD Noor Al-Busaidi (Oman)
	11.00-11.30	COFFEE BREAK	10.45-11.15	COFFEE BREAK	COFFEE BREAK
	11.30 – 12.15	Metabolism and Protective Properties of HDL Philip Barter (Australia)	11.15 – 12.00	Agents to Raise HDL (Do We Have the Right Biomarker of HDL Function?) Khalid Al-Rasadi (Oman)	Statin Tolerability: Overcoming the Treatment Gap Zuhair Awan (KSA)
	12.15 – 13.00	PCSK9 and its Role in LDL Receptor Regulation Gilles Lambert (France)	12.00 – 12.45	Metabolism, Atherogenic Properties and Agents to Reduce Lipoprotein(a) Dimitri Mikhailidis (UK)	Gender Differences in Lipid Management and CVD Lessons Learned from Gulf Surveys Wael Almahmeed (UAE)
			12:45 – 13:00	Participant's Debate Session: The use of Statin vs No-statin in The Management of Dyslipidemia (All Faculty)	Participant's Debate Session: The Use of LDL-C vs Non-HDL-C in the Management of Dyslipidemia (All Faculty)
	13.00 – 14.30	LUNCH	13.00 – 14.30	LUNCH	LUNCH

**Dyslipidemia Working Group (DWG) under the
umbrella of Gulf Heart Association (GHA)**



The list of Members:

The group will consist of clinicians and scientist interested in the field of lipid and atherosclerosis.

Khalid Al-Rasadi, Oman (Lipidology), Chairman

Khalid Al-Waili, Oman (Lipidology)

Fahad Al-Zadjali, Oman (Biochemistry)

Wael Almahmed, UAE (Cardiology)

Khalid AlHabib, KSA (Cardiology)

Zuhair Awan, KSA (Lipidology)

Fahad Al-Nahdi, KSA (Cardiology)